Search

Displaying results 4811 - 4820 of 10000 in total
  1. Drug

    Propicillin

    go.drugbank.com/drugs/DB13660
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties. … Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin.

  3. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

  4. Drug

    Guvacine

    go.drugbank.com/drugs/DB08848
    Experimental

    Guvacine is a pyridine alkaloid found in the Areca nut (also known as the Betel nut). It is an experimental drug with no approved indication. … Currently it has been determined that guvacine is a specific GABA reuptake inhibitor with no significant affinity at GABA receptors.

  5. Drug

    Troxacitabine

    go.drugbank.com/drugs/DB04961
    Investigational

    Troxacitabine is a nucleoside analog with antineoplastic activity. There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

  6. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. … Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc. The annual average price of Asfotase Alfa treatment is $285,000.

  7. Drug

    Riferminogene pecaplasmid

    go.drugbank.com/drugs/DB06394
    Investigational

    Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.

  8. Drug

    Enviomycin

    go.drugbank.com/drugs/DB08993
    Experimental

    It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

    Categories: Antiinfectives for Systemic Use
  9. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial. … CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia.

  10. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    It is developed by Insmed and is currently under phase I of the clinical trial. … rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models